Niacinamide, a vitamin B3 supplement studied against skin cancer, has its best human support for fewer new skin cancers in people with heavily sun-damaged skin and earlier skin cancer. The benefit fades once stopped and failed after organ transplant. Eye signals are early, slowing aging unshown in people. Mostly mild digestive side effects at skin-trial doses; low platelets on dialysis. A targeted skin-cancer measure, not an established longevity treatment. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Platelet count | 150–450 ×10⁹/L | Falls with nicotinamide in kidney failure |
| ALT | 7–56 U/L | Liver injury at high doses |
| Serum creatinine with eGFR | Creatinine 0.7–1.3 mg/dL | Reduced clearance raises exposure and platelet risk |
| Fasting glucose | 70–99 mg/dL | Gram doses reduced insulin sensitivity |
| Serum phosphate (dialysis only) | 2.5–4.5 mg/dL | Falls with nicotinamide |
| Actinic keratosis and new skin cancer count | No established target; change from own baseline count | Lower counts during use |
| Visual field mean deviation (glaucoma only) | No established target; rate of change from own baseline | Under study |
| Carbamazepine or primidone drug level (users only) | Not specified in the ER | Nicotinamide slows their metabolism |
Cadence: Baseline complete blood count, liver enzymes, kidney function and fasting glucose, plus a drug level with carbamazepine or primidone; blood tests at 8–12 weeks after starting or a dose increase, then every 6–12 months; skin examinations every 3–6 months; visual fields at the interval set by the treating ophthalmologist. Below 1,500 mg/day, routine adverse-effect monitoring may not be indicated.